Actively Recruiting
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Led by Bettina Mittendorfer · Updated on 2025-07-22
60
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
Sponsors
B
Bettina Mittendorfer
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: * screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and magnetic resonance spectroscopy \[MRS\] scans) * Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies
CONDITIONS
Official Title
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Not pregnant or breastfeeding
- Weight stable and sedentary before enrollment
- No use of tobacco products, excessive alcohol, dietary supplements, or medications known to affect glucose and lipid metabolism (except some diabetes medications for metabolically abnormal obesity group)
- No significant organ system dysfunction or disease such as chronic severe kidney disease or cancer
- Lean group: BMI 18.5 to less than 25.0 kg/m2, intrahepatic triglyceride (IHTG) content less than 5%, fasting blood glucose less than 100 mg/dl, blood glucose 2 hours after 75 g oral glucose challenge less than 140 mg/dl, HbA1c less than 5.7%
- Metabolically normal obesity group: BMI 30.0 to less than 45.0 kg/m2, IHTG content less than 5%, fasting blood glucose less than 100 mg/dl, blood glucose 2 hours after 75 g oral glucose challenge less than 140 mg/dl, HbA1c less than 5.7%
- Metabolically abnormal obesity group: BMI 30.0 to less than 45.0 kg/m2, IHTG content greater than 7.5%, fasting blood glucose 100 to less than 126 mg/dl, blood glucose 2 hours after 75 g oral glucose challenge 140 to less than 200 mg/dl, HbA1c 5.7 to less than 6.4%
- Metabolically abnormal obesity type 2 diabetes group: BMI 30.0 to less than 45.0 kg/m2, clinical diagnosis of type 2 diabetes or fasting blood glucose over 126 mg/dl or blood glucose 2 hours after 75 g oral glucose challenge over 200 mg/dl or HbA1c over 6.4% without medication if not medically treated for diabetes
You will not qualify if you...
- Individuals who do not meet all inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Missouri School of Medicine
Columbia, Missouri, United States, 65212
Actively Recruiting
Research Team
H
Heather McHatton
CONTACT
A
Aman Pritish Aher
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here